Azvudine beats paxlovid in reducing COVID-19 deaths

Azvudine beats paxlovid in reducing COVID-19 deaths

Source: News-Medical.Net

In hospitalized COVID-19 patients, azvudine shows lower all-cause mortality and fewer adverse events than Paxlovid, with added antitumor effects observed.

A large-scale study reveals azvudine’s comparable efficacy to Paxlovid, fewer adverse effects, and potential antitumor benefits in patients with liver cancer.
Study: Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (… [5648 chars]

Read more